

Nishida Naoshi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6755519/publications.pdf>

Version: 2024-02-01

71
papers

2,931
citations

201674

27
h-index

175258

52
g-index

72
all docs

72
docs citations

72
times ranked

3718
citing authors

#	ARTICLE	IF	CITATIONS
1	Current Perspectives on the Immunosuppressive Niche and Role of Fibrosis in Hepatocellular Carcinoma and the Development of Antitumor Immunity. <i>Journal of Histochemistry and Cytochemistry</i> , 2022, 70, 53-81.	2.5	6
2	Clinical Significance of the Duality of Wnt/ β -Catenin Signaling in Human Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 444.	3.7	20
3	Value of artificial intelligence with novel tumor tracking technology in the diagnosis of gastric submucosal tumors by contrast-enhanced harmonic endoscopic ultrasonography. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 841-846.	2.8	10
4	Artificial intelligence (AI) models for the ultrasonographic diagnosis of liver tumors and comparison of diagnostic accuracies between AI and human experts. <i>Journal of Gastroenterology</i> , 2022, 57, 309-321.	5.1	19
5	Objective Response Predicts Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapies. <i>Clinical Cancer Research</i> , 2022, 28, 3443-3451.	7.0	19
6	Role of phlebotomy in the treatment of liver damage related to erythropoietic porphyria. <i>Scientific Reports</i> , 2022, 12, 6100.	3.3	4
7	Serum Levels of α -Fetoprotein Increased More Than 10 Years Before Detection of Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 162-170.e4.	4.4	24
8	Should Contrast-Enhanced Harmonic Endoscopic Ultrasound Be Incorporated into the International Consensus Guidelines to Determine the Appropriate Treatment of Intraductal Papillary Mucinous Neoplasm?. <i>Journal of Clinical Medicine</i> , 2021, 10, 1818.	2.4	0
9	Clinicopathological analysis of hepatic immune-related adverse events in comparison with autoimmune hepatitis and graft-versus host disease. <i>Scientific Reports</i> , 2021, 11, 9242.	3.3	9
10	Usefulness of the Novel Snare-over-the-Guidewire Method for Transpapillary Plastic Stent Replacement (with Video). <i>Journal of Clinical Medicine</i> , 2021, 10, 2858.	2.4	2
11	Improved Tumor Response to Lenvatinib Re-Treatment after Failure of Immune Checkpoint Inhibitors in a Patient with Advanced Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021, 10, 535-538.	7.7	2
12	Role of Oncogenic Pathways on the Cancer Immunosuppressive Microenvironment and Its Clinical Implications in Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 3666.	3.7	25
13	Higher Enhancement Intrahepatic Nodules on the Hepatobiliary Phase of Gd-EOB-DTPA-Enhanced MRI as a Poor Responsive Marker of Anti-PD-1/PD-L1 Monotherapy for Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021, 10, 615-628.	7.7	31
14	Immunological Microenvironment Predicts the Survival of the Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 Antibody. <i>Liver Cancer</i> , 2021, 10, 380-393.	7.7	51
15	Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021, 10, 583-592.	7.7	33
16	Deep-learning framework based on a large ultrasound image database to realize computer-aided diagnosis for liver and breast tumors. , 2021, , .		3
17	Accumulation of Genetic and Epigenetic Alterations in the Background Liver and Emergence of Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease. <i>Cells</i> , 2021, 10, 3257.	4.1	6
18	Efficacy of a modified double-guidewire technique using an uneven double lumen cannula (uneven) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Endoscopy and Other Interventional Techniques, 2020, 34, 1432-1441.	2.4	18

#	ARTICLE	IF	CITATIONS
19	Clinical implications of the dual blockade of the PD-1/PD-L1 and vascular endothelial growth factor axes in the treatment of hepatocellular carcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 640-643.	1.5	5
20	Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD-1/PD-L1 Checkpoint Blockade. <i>Cancers</i> , 2020, 12, 3048.	3.7	37
21	Artificial Intelligence in Medical Imaging and Its Application in Sonography for the Management of Liver Tumor. <i>Frontiers in Oncology</i> , 2020, 10, 594580.	2.8	21
22	Association between Genetic and Immunological Background of Hepatocellular Carcinoma and Expression of Programmed Cell Death-1. <i>Liver Cancer</i> , 2020, 9, 426-439.	7.7	26
23	Optimal cropping for input images used in a convolutional neural network for ultrasonic diagnosis of liver tumors. <i>Japanese Journal of Applied Physics</i> , 2020, 59, SKKE09.	1.5	6
24	Long-term prognosis and management of hepatocellular carcinoma after curative treatment. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 480-483.	8.9	12
25	Immune Phenotype and Immune Checkpoint Inhibitors for the Treatment of Human Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 1274.	3.7	27
26	Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept Study. <i>Cancers</i> , 2019, 11, 1084.	3.7	200
27	Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study. <i>Cancers</i> , 2019, 11, 952.	3.7	114
28	Switching from entecavir to tenofovir alafenamide versus maintaining entecavir for chronic hepatitis B. <i>Journal of Medical Virology</i> , 2019, 91, 1804-1810.	5.0	28
29	Current status and perspectives for computer-aided ultrasonic diagnosis of liver lesions using deep learning technology. <i>Hepatology International</i> , 2019, 13, 416-421.	4.2	24
30	Computer aided diagnosis system developed for ultrasound diagnosis of liver lesions using deep learning. , 2019, , .		15
31	Liver damage related to immune checkpoint inhibitors. <i>Hepatology International</i> , 2019, 13, 248-252.	4.2	36
32	Value of additional endoscopic ultrasonography for surveillance after surgical removal of intraductal papillary mucinous neoplasms. <i>Digestive Endoscopy</i> , 2018, 30, 659-666.	2.3	10
33	Molecular Scoring of Hepatocellular Carcinoma for Predicting Metastatic Recurrence and Requirements of Systemic Chemotherapy. <i>Cancers</i> , 2018, 10, 367.	3.7	24
34	Immune checkpoint blockade for the treatment of human hepatocellular carcinoma. <i>Hepatology Research</i> , 2018, 48, 622-634.	3.4	58
35	Cystic duct antegrade stenting for cholangitis after the long-term deployment of lumen-apposing metal stents for calculous cholecystitis. <i>Endoscopic Ultrasound</i> , 2018, 7, 349.	1.5	1
36	Stress Response Protein RBM3 Promotes the Development of Colitis-associated Cancer. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 66-74.	1.9	5

#	ARTICLE	IF	CITATIONS
37	Rescue EUS-guided intrahepatic biliary drainage for malignant hilar biliary stricture after failed transpapillary re-intervention. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2017, 31, 4764-4772.	2.4	40
38	MicroRNAs for the Prediction of Early Response to Sorafenib Treatment in Human Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2017, 6, 113-125.	7.7	50
39	Role of Immune Checkpoint Blockade in the Treatment for Human Hepatocellular Carcinoma. <i>Digestive Diseases</i> , 2017, 35, 618-622.	1.9	10
40	Time to Transcatheter Arterial Chemoembolization Refractoriness in Patients with Hepatocellular Carcinoma in Kinki Criteria Stages B1 and B2. <i>Digestive Diseases</i> , 2017, 35, 589-597.	1.9	40
41	Impact of Tumor Factors on Survival in Patients with Hepatocellular Carcinoma Classified Based on Kinki Criteria Stage B2. <i>Digestive Diseases</i> , 2017, 35, 583-588.	1.9	7
42	Contribution of C1485T mutation in the HBx gene to human and murine hepatocarcinogenesis. <i>Scientific Reports</i> , 2017, 7, 10440.	3.3	3
43	Gankyrin induces STAT3 activation in tumor microenvironment and sorafenib resistance in hepatocellular carcinoma. <i>Cancer Science</i> , 2017, 108, 1996-2003.	3.9	40
44	Immunological Microenvironment of Hepatocellular Carcinoma and Its Clinical Implication. <i>Oncology</i> , 2017, 92, 40-49.	1.9	100
45	Oncogenic Signal and Tumor Microenvironment in Hepatocellular Carcinoma. <i>Oncology</i> , 2017, 93, 160-164.	1.9	56
46	Unique features associated with hepatic oxidative DNA damage and DNA methylation in non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1646-1653.	2.8	49
47	Clinical Significance of Epigenetic Alterations in Human Hepatocellular Carcinoma and Its Association with Genetic Mutations. <i>Digestive Diseases</i> , 2016, 34, 708-713.	1.9	17
48	Monoethanolamine Oleate Sclerotherapy for Polycystic Liver Disease. <i>Digestive Diseases</i> , 2016, 34, 654-658.	1.9	5
49	Validation of a Modified Substaging System (Kinki Criteria) for Patients with Intermediate-Stage Hepatocellular Carcinoma. <i>Oncology</i> , 2015, 89, 47-52.	1.9	31
50	Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2015, 4, 253-262.	7.7	172
51	Molecular Mechanism and Prediction of Sorafenib Chemoresistance in Human Hepatocellular Carcinoma. <i>Digestive Diseases</i> , 2015, 33, 771-779.	1.9	76
52	Hepatic DNA Methylation Is Affected by Hepatocellular Carcinoma Risk in Patients with and without Hepatitis Virus. <i>Digestive Diseases</i> , 2015, 33, 745-750.	1.9	9
53	Serum miR-21, miR-29a, and miR-125b Are Promising Biomarkers for the Early Detection of Colorectal Neoplasia. <i>Clinical Cancer Research</i> , 2015, 21, 4234-4242.	7.0	128
54	Impaired expression of ATP-binding cassette transporter G2 and liver damage in erythropoietic protoporphyria. <i>Hepatology</i> , 2015, 62, 1638-1639.	7.3	9

#	ARTICLE	IF	CITATIONS
55	Subclassification of BCLC B Stage Hepatocellular Carcinoma and Treatment Strategies: Proposal of Modified Bolondi's Subclassification (Kinki Criteria). <i>Digestive Diseases</i> , 2015, 33, 751-758.	1.9	167
56	Identification of Epigenetically Inactivated Genes in Human Hepatocellular Carcinoma by Integrative Analyses of Methylation Profiling and Pharmacological Unmasking. <i>Digestive Diseases</i> , 2014, 32, 740-746.	1.9	12
57	Genome-Wide Profiling of DNA Methylation and Tumor Progression in Human Hepatocellular Carcinoma. <i>Digestive Diseases</i> , 2014, 32, 658-663.	1.9	25
58	Alteration of Epigenetic Profile in Human Hepatocellular Carcinoma and Its Clinical Implications. <i>Liver Cancer</i> , 2014, 3, 417-427.	7.7	38
59	Recent Advancements in Comprehensive Genetic Analyses for Human Hepatocellular Carcinoma. <i>Oncology</i> , 2013, 84, 93-97.	1.9	56
60	Impact of peginterferon alpha-2b and entecavir hydrate combination therapy on persistent viral suppression in patients with chronic hepatitis B. <i>Journal of Medical Virology</i> , 2013, 85, 987-995.	5.0	19
61	Unique Association between Global DNA Hypomethylation and Chromosomal Alterations in Human Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2013, 8, e72312.	2.5	31
62	Gender Differences in the Livers of Patients with Hepatocellular Carcinoma and Chronic Hepatitis C Infection. <i>Digestive Diseases</i> , 2012, 30, 547-553.	1.9	9
63	Characteristic patterns of altered DNA methylation predict emergence of human hepatocellular carcinoma. <i>Hepatology</i> , 2012, 56, 994-1003.	7.3	129
64	Genetic and Epigenetic Signatures in Human Hepatocellular Carcinoma:A Systematic Review. <i>Current Genomics</i> , 2011, 12, 130-137.	1.6	165
65	Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma. <i>Hepatology</i> , 2008, 47, 908-918.	7.3	250
66	High copy amplification of the aurora-A gene is associated with chromosomal instability phenotype in human colorectal cancers. <i>Cancer Biology and Therapy</i> , 2007, 6, 525-533.	3.4	75
67	Extensive Methylation Is Associated with β -Catenin Mutations in Hepatocellular Carcinoma: Evidence for Two Distinct Pathways of Human Hepatocarcinogenesis. <i>Cancer Research</i> , 2007, 67, 4586-4594.	0.9	57
68	Discrete breakpoint mapping and shortest region of overlap of chromosome arm 1q gain and 1p loss in human hepatocellular carcinoma detected by semiquantitative microsatellite analysis. <i>Genes Chromosomes and Cancer</i> , 2005, 42, 34-43.	2.8	27
69	Alteration of the p14 ARF gene and p53 status in human hepatocellular carcinomas. <i>Journal of Gastroenterology</i> , 2004, 39, 355-361.	5.1	27
70	Prognostic Impact of Multiple Allelic Losses on Metastatic Recurrence in Hepatocellular Carcinoma after Curative Resection. <i>Oncology</i> , 2002, 62, 141-148.	1.9	22
71	Comprehensive allelotyping of well-differentiated human hepatocellular carcinoma with semiquantitative determination of chromosomal gain or loss. <i>Genes Chromosomes and Cancer</i> , 2002, 35, 329-339.	2.8	36